Biohaven Pharmaceuticals and XVIVO teamed up again, this time to create a mechanism of action animation for BHV-7000, their recently-acquired Kv7 activator. The BHV-7000 molecule blocks the action of the voltage-gated Kv7 potassium ion channel, which exquisitely regulates the excitability of neurons in the central nervous system.
MPO inhibition in MSA and ALS Animation
By
Jordan Maire
We are very fortunate to work with Biohaven Pharmaceuticals on many rewarding medical animations, and this one was no exception. The challenge for this project was to illuminate the science of myeloperoxidase (MPO), and how it is a potential target for treatment in multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS).
BRAIN SHUTTLE
By
admin
The blood-brain barrier (BBB) is a highly selective membrane system that prevents unwanted passage of molecules into the brain extracellular fluid. Consequently, the BBB also significantly hinders the effectiveness of drugs used to treat a number of neurological disorders. Roche has engineered a protein module that can greatly enhance the passage of therapeutic agents across the blood-brain barrier. This 3D medical animation depicts the mechanism by which the “Brain Shuttle” module operates.
GLUTAMATE MODULATION
By
admin
Glutamate is the most abundant excitatory neurotransmitter in the brain. Release of glutamate is essential for normal function of neurons, but the levels of this neurotransmitter must be tightly regulated to avoid toxic effects on neurons. XVIVO partnered with Biohaven to animate the glutamate story.
NEURALINK
By
Jordan Maire
XVIVO created an animation that provides a 30,000-foot overview of neurophysiological signaling in the human brain to help the team at Neuralink describe the science that underpins their brain-machine interface development.
Can't Get Enough of XVIVO?
We’ve got you covered! Check out our latest wallpapers for stunning visuals!
Biohaven Pharmaceuticals and XVIVO teamed up again, this time to create a mechanism of action animation for BHV-7000, their recently-acquired Kv7 activator. The BHV-7000 molecule blocks the action of the voltage-gated Kv7 potassium ion channel, which exquisitely regulates the excitability of neurons in the central nervous system.
